news

Our latest
Press Releases & Updates

Latest press releases

RetinAI and PulseSight Therapeutics Expand Collaboration to Support Advancement of PST-611 Gene Therapy Program for Geographic Atrophy into Phase 2a

RetinAI and PulseSight Therapeutics expand their collaboration to support PST-611, an investigational gene therapy for geographic atrophy, from AI-based analysis of Phase 1 OCT data through the upcoming Phase 2a trial.

Heidelberg Engineering and RetinAI Expand Ophthalmology Offering with Selected RetinAI Discovery® for Clinics Solutions

RetinAI OCT Atlas® is now CE-marked for Clinical Use: one algorithm for AMD, DR, DME, and Glaucoma

RetinAI OCT Atlas® is now CE-marked under EU MDR 2017/745 for clinical use across AMD, Diabetic Retinopathy, DME, and Glaucoma, validated in the DILL study across 124 patients and three OCT devices.

RetinAI & OptymEdge Collaborate to Accelerate Ophthalmic Drug Development Through AI-Powered Reading Center Solutions

RetinAI in RTS- Swiss television

The last week of August we received the Swiss Television (SRF - Schweizer Radio und Fernsehen) at our offices in Bern.We talked for a few minutes about what we do and how artificial intelligence is going to change ophthalmology and healthcare in the near future!
‍
Watch it here

Arvo 2019 - Vancouver [MAY’19]

RetinAI had a great conference at this year at ARVO 2019, with more than 15’000 attendees from all over the world!Congratulations to the team for these amazing 5 days of work and for the success on the official release of our two main products: OmniViewer and RetinAI Discovery.

Democratising Access to Health Care - INVESTIERE [APRIL’19]

"Automation does not replace jobs, it replaces tasks" - Learn how RetinAI applies machine learning to medical imaging, not to replace eye doctors, but to make their work less tedious. Via Investiere Venture Capital - Read more

RetinAI in FORBES FR [DECEMBER’18]

RetinAI is honoured to be in December's edition of Forbes France! Artificial Intelligence is changing the world of ophthalmology by democratising access to high-quality eye-care for everyone. Discover a bit more about the future of healthcare in 2019, starting with your eyes! [FR]

‍

Our latest
Press Releases & Updates

Latest press releases

RetinAI and PulseSight Therapeutics Expand Collaboration to Support Advancement of PST-611 Gene Therapy Program for Geographic Atrophy into Phase 2a

Heidelberg Engineering and RetinAI Expand Ophthalmology Offering with Selected RetinAI Discovery® for Clinics Solutions

RetinAI OCT Atlas® is now CE-marked for Clinical Use: one algorithm for AMD, DR, DME, and Glaucoma

RetinAI & OptymEdge Collaborate to Accelerate Ophthalmic Drug Development Through AI-Powered Reading Center Solutions

Latest updates

RetinAI in RTS- Swiss television

Arvo 2019 - Vancouver [MAY’19]

Democratising Access to Health Care - INVESTIERE [APRIL’19]

RetinAI in FORBES FR [DECEMBER’18]

Contact us for more informations! We are happy to hear from you!

Sign Up And Receive Our Latest Promotions!

Our latest Press Releases & Updates

Latest press releases

RetinAI and PulseSight Therapeutics Expand Collaboration to Support Advancement of PST-611 Gene Therapy Program for Geographic Atrophy into Phase 2a

Heidelberg Engineering and RetinAI Expand Ophthalmology Offering with Selected RetinAI Discovery® for Clinics Solutions

RetinAI OCT Atlas® is now CE-marked for Clinical Use: one algorithm for AMD, DR, DME, and Glaucoma

RetinAI & OptymEdge Collaborate to Accelerate Ophthalmic Drug Development Through AI-Powered Reading Center Solutions

Latest updates

RetinAI in RTS- Swiss television

Arvo 2019 - Vancouver [MAY’19]

Democratising Access to Health Care - INVESTIERE [APRIL’19]

RetinAI in FORBES FR [DECEMBER’18]

Contact us for more informations! We are happy to hear from you!

Our latest
Press Releases & Updates